Oncology · Hematologic Malignancies
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
The peripheral blood smear in Acute Myelogenous Leukemia (AML) classically reveals Auer rods, which are needle-like azurophilic cytoplasmic inclusions.
Marrow or blood blasts ≥20% remain the general diagnostic threshold for AML, but this no longer applies to AML with defining recurrent genetic abnormalities: under WHO 5th edition (2022) no blast threshold is required for entities such as PML::RARA, RUNX1::RUNX1T1, CBFB::MYH11, or mutated NPM1 (BCR::ABL1 and mutated CEBPA still require ≥20%), while ICC 2022 lowers the threshold to ≥10% for the same entities.
Acute Promyelocytic Leukemia (APL), a subtype of AML, is associated with the t(15;17) translocation producing the PML::RARA fusion (WHO 2022 entity: acute promyelocytic leukaemia with PML::RARA) and carries a high risk of disseminated intravascular coagulation (DIC).
All-trans retinoic acid (ATRA) combined with arsenic trioxide (ATO) is the standard, largely chemotherapy-free, life-saving regimen for APL; ATRA induces differentiation of the malignant promyelocytes and should be started on clinical suspicion, before genetic confirmation, to blunt the coagulopathy.
Patients with AML frequently present with pancytopenia, leading to clinical manifestations of fatigue, recurrent infections, and mucosal bleeding.
Myeloperoxidase (MPO) positivity establishes myeloid lineage and distinguishes myeloid blasts from lymphoid blasts, but MPO is negative in AML with minimal differentiation and in many monoblastic cases, where flow cytometry (CD13, CD33, CD117) and nonspecific esterase are required.
Tumor lysis syndrome is a critical, life-threatening complication during induction chemotherapy, characterized by hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia.
Vignette unlocked
A 45-year-old male presents to the emergency department with a two-week history of progressive fatigue, night sweats, and easy bruising. Physical examination reveals gingival hyperplasia and multiple petechiae on the lower extremities. Laboratory studies demonstrate a hemoglobin of 7.2 g/dL, a platelet count of 22,000/µL, and a white blood cell count of 45,000/µL. A peripheral blood smear shows numerous myeloblasts containing Auer rods.
What is the most likely diagnosis?
Acute Myelogenous Leukemia (AML)
The presence of >20% blasts in the bone marrow (implied by the high peripheral blast count) combined with the pathognomonic finding of Auer rods confirms the diagnosis of AML.
Full handout
High yield triage
Etiology / Epidemiology
Primarily affects older adults (median age about 68–69). Risk factors include prior chemotherapy (alkylating agents), radiation, and benzene exposure.
Clinical Manifestations
Presents with pancytopenia symptoms: fatigue, infection, and bleeding. Auer rods are the pathognomonic finding on peripheral smear.
Diagnosis
Bone marrow biopsy showing at least 20% myeloblasts is the diagnostic threshold.
Treatment
Induction therapy with cytarabine plus an anthracycline (e.g., daunorubicin). Tumor lysis syndrome is a major emergency.
Prognosis
Prognosis is highly variable based on cytogenetics; overall 5-year survival is approximately 30-35%.
Full handout
Epidemiology & Etiology
AML is the most common acute leukemia in adults, with incidence increasing significantly after age 60. Secondary AML often follows exposure to topoisomerase II inhibitors or alkylating agents used for prior malignancies. Genetic predispositions like Down syndrome (specifically M7 subtype) also increase risk.
Pertinent Anatomy
The disease originates in the bone marrow hematopoietic stem cells. Infiltration of the marrow space leads to the displacement of normal hematopoiesis, resulting in systemic cytopenias.
Pathophysiology
Malignant transformation of myeloid progenitor cells results in a maturation arrest. These immature myeloblasts proliferate uncontrollably, failing to differentiate into functional granulocytes, erythrocytes, or platelets. This leads to bone marrow failure and the clinical triad of anemia, neutropenia, and thrombocytopenia.
Clinical Manifestations
Patients present with constitutional symptoms including fever, night sweats, and weight loss. Physical exam may reveal gingival hyperplasia (characteristic of AML with monocytic or myelomonocytic differentiation, formerly FAB M4/M5), hepatosplenomegaly, and petechiae. Leukostasis is a medical emergency characterized by dyspnea and altered mental status due to hyperleukocytosis.
Diagnosis
The bone marrow biopsy is the gold standard for diagnosis, requiring at least 20% myeloblasts in the marrow or peripheral blood. Peripheral smear often reveals Auer rods, which are needle-like cytoplasmic inclusions. Flow cytometry is essential to confirm the myeloid lineage of the blasts.
Treatment
Induction therapy consists of the '7+3' regimen: cytarabine for 7 days and an anthracycline for 3 days. Tumor lysis syndrome requires aggressive IV hydration and allopurinol or rasburicase. Consolidation therapy follows to achieve long-term remission, often involving allogeneic stem cell transplant in high-risk patients. For older or unfit patients, venetoclax plus a hypomethylating agent (azacitidine or decitabine) has replaced intensive 7+3 induction as the standard of care.
Prognosis
Prognosis is dictated by cytogenetic markers; favorable markers include t(8;21), while unfavorable include complex or monosomal karyotypes and TP53, ASXL1, or RUNX1 mutations; under ELN 2022, FLT3-ITD without other adverse lesions is now classified as intermediate risk regardless of allelic ratio. Disseminated intravascular coagulation (DIC) is a frequent, life-threatening complication, particularly in acute promyelocytic leukaemia with PML::RARA (formerly FAB M3).
Differential Diagnosis
Acute Lymphoblastic Leukemia: usually pediatric, PAS-positive blasts
Chronic Myelogenous Leukemia: presence of Philadelphia chromosome, mature cells
Aplastic Anemia: hypocellular marrow without blast proliferation
Myelodysplastic Syndrome: <20% blasts, dysplastic morphology
Leukemoid Reaction: elevated WBC count due to infection, not malignancy